Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations

MIAMI, March 31, 2015 /PRNewswire/ -- Biorasi, a full-service CRO powered by TALOS™, today announced a strategic partnership with Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences. Offering therapeutic expertise in a number of areas, the global CRO has deployed Medidata's electronic data capture (EDC), management and reporting system, Medidata Rave®, to support Biorasi's Phase I through IV global clinical trial business.

"Biorasi's adoption of Rave has greatly benefited our clinical trials process. The dynamic, easy-to-use technology offers our platform TALOS™ the power to do more compared to other EDC systems," says Dr Boris Reznik, Chairman of Biorasi. "We plan to double in growth this year due to the rising demand of Biosimilars and Interchangeables studies from leading pharmaceutical companies around the world. Utilizing enterprise suite technology allows us to fully leverage our core competency of trial optimization."

As a Medidata Services Partner, Biorasi and its customers gain the advantages of a multi-dimensional, full suite of Medidata products to optimize clinical trial operations and save costs, reduce timelines and mitigate risk. In addition to Rave, the CRO is currently working towards gaining accreditations in Medidata's electronic patient-reported outcome (ePRO) solution for patient-centric data capture (Medidata Patient Cloud®), and Medidata's medical coding solution (Medidata Coder®).

"We are very pleased to have Biorasi join the Medidata Partner Ecosystem and look forward to growing and innovating jointly in this very exciting time of emerging Biosimilars development," says Medidata SVP of Global Partner Business, Pat Bernard. "Medidata can support Biorasi's mission of developing and implementing groundbreaking methods of optimizing clinical research with the scalable, flexible and easily configurable nature of the Medidata Clinical Cloud® and help Biorasi in its innovative efforts to deliver successful new treatments for time-critical indications."